Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Oncolytics Biotech Inc. (ONC) announced its China-based partner reported the results of its pelareorep-paclitaxel combination therapy for advanced breast cancer
  • The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events reported to date
  • Disease control, partial response, or stable disease was achieved in 93 per cent of patients
  • 86 per cent of which showed tumour shrinkage activity
  • One patient achieved a partial at week eight, maintained the response until week 48, and remained on the study
  • Oncolytics BiotechInc. (ONC) is down 1.28 per cent and is trading at $2.32 per share as of 2:15 p.m. EST

Oncolytics Biotech (ONC) partner, Adlai Nortye, reported results from a clinical evaluation of pelareorep-paclitaxel combination therapy for advanced breast cancer.

The studied combination has been well tolerated, with no dose-limiting toxicities or serious adverse events reported to date.

Fifteen patients were treated in the trial, with fourteen having had at least one post-baseline tumour assessment. All patients enrolled in the trial were previously treated with at least one endocrine therapy and no more than one line of chemotherapy for recurrent or metastatic disease.

Disease control, partial response, or stable disease was achieved in thirteen of the patients, twelve of which showed tumour shrinkage from baseline.

Seven of fourteen evaluable patients achieved a partial response to the therapy. One patient who achieved a partial at week eight maintained the response until week 48 and remained on the study.

Data from the trial is expected to fast-track Adlai Nortye’s development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics’ North American metastatic breast cancer trials, IND-213 and BRACELET-1.

Oncolytics expects to report the overall response rate, PFS, and evolving overall survival data from the ongoing BRACELET-1 trial in the first half of 2023.

Oncolytics BiotechInc. (ONC) is down 1.28 per cent and is trading at $2.32 per share as of 2:15 p.m. EST.


More From The Market Herald

" Osisko Metals (TSXV:OM) invites investors to join them at the Vancouver Resource Investment Conference

Osisko Metals (OM) invites investors to attend the Vancouver Resource Investment Conference (VRIC).

" Plurilock (TSXV:PLUR) appoints Blake Corbet to its Board of Directors

The duo-listed cybersecurity solutions provider, Plurilock Security (PLUR), appoints Blake Corbet to its Board of Directors.

" Current Water Technologies (TSXV:WATR) signs agreement with Singapore-based Separtis Technologies Global

Current Water Technologies (WATR) has established a binding memorandum of agreement with Separtis Technologies Global Pte Ltd of Singapore.

" St Charles Resources (TSXV:SCRS.P) signs new agreement for qualifying transaction with Eastern Resources OOD

St Charles Resources (SCRS.P) has signed a business combination agreement with Eastern Resources OOD Eastern Resources.